Content and data provided by various third parties and Fidelity − Terms of Use

Stock Details

RELATED RESOURCES

News & Events:RMD

RESMED INC

239.99Down -0.86 (-0.3571 %)as of 4:10:00pm ET 08/12/2022

Quotes delayed at least 15 min. Log in for real time quote.

Log in for more news Show all article details.Expand all| Hide all article details.Collapse all
  1. Show article details.

    What 3 Analyst Ratings Have To Say About ResMed

    Benzinga – 6:23 PM ET 04/29/2022

    Over the past 3 months, 3 analysts have published their opinion on ResMed stock. According to 3 analyst offering 12-month price targets in the last 3 months, ResMed has an average price target of $263.0 with a high of $280.00 and a low of $233.00. Below is a summary of how these 3 analysts rated ResMed over the past 3 months.
  2. Show article details.

    ResMed's Q3 Earnings Short Of Expectations, Profit Margins Contract

    Benzinga – 7:50 AM ET 04/29/2022

    ResMed's Q3 Earnings Short Of Expectations, Profit Margins Contract
  3. Show article details.

    ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2022

    GlobeNewswire – 4:05 PM ET 04/28/2022

    Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, April 28, 2022 -- ResMed Inc. (RMD) today announced results for its quarter ended March 31, 2022.
  4. Show article details.

    Earnings Scheduled For April 28, 2022

    Benzinga – 4:50 AM ET 04/28/2022

      ** PBF Energy is projected to report quarterly earnings at $0.26 per share on revenue of $8.24 billion. ** Merck & Co is estimated to report quarterly earnings at $1.83 per share on revenue of $14.68 billion. ** Smith & Nephew is estimated to report earnings for its first quarter. ** Domino's Pizza is estimated to report quarterly earnings at $3.05 per share on revenue of $1.03 billion.
  5. Show article details.

    ResMed Announces Participation in the 24th Annual Macquarie Australia Conference

    GlobeNewswire – 4:05 PM ET 04/27/2022

    ResMed (RMD) today announced Brett Sandercock, chief financial officer, will present virtually at the Macquarie Australia Conference on Tuesday, May 3, 2022, beginning at approximately 8:45 a.m. via video webcast.
  6. Show article details.

    Earnings Outlook For ResMed

    Benzinga – 12:04 PM ET 04/27/2022

    ResMed is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Analysts estimate that ResMed will report an earnings per share of $1.42. ResMed bulls will hope to hear the company to announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
  7. Show article details.

    ResMed to Report Third Quarter Fiscal 2022 Earnings on April 28, 2022

    GlobeNewswire – 4:05 PM ET 04/07/2022

    ResMed (RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2022 on Thursday, April 28, 2022, after the New York Stock Exchange closes.
  8. Show article details.

    What 5 Analyst Ratings Have To Say About ResMed

    Benzinga – 1:09 PM ET 04/06/2022

    ResMed has observed the following analyst ratings within the last quarter: These 5 analysts have an average price target of $265.0 versus the current price of ResMed at $243.885, implying upside. Below is a summary of how these 5 analysts rated ResMed over the past 3 months.
  9. Show article details.

    Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022

    Benzinga – 10:16 AM ET 04/06/2022

    According to Morgan Stanley, the prior rating for Royalty Pharma PLC was changed from Equal-Weight to Overweight. According to Keefe, Bruyette & Woods, the prior rating for PJT Partners Inc was changed from Market Perform to Outperform. Guggenheim upgraded the previous rating for Array Technologies Inc from Neutral to Buy.
  10. Show article details.

    Markets Fall Amid Rising Oil Prices

    Benzinga – 4:09 PM ET 03/23/2022

    U.S. indices finished lower Wednesday as investors continue to weigh the Federal Reserve tapering outlook, inflation concerns and the Russia-Ukraine war. Here are the day's winners and losers from the S&P 500, according to data from Benzinga Pro. Hess Corp., Marathon Oil Corporation and Baker Hughes Co were among the top gainers for the SPY Wednesday. Charles River Laboratories Intl.
  11. Show article details.

    ResMed Announces Participation in the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum

    GlobeNewswire – 4:05 PM ET 03/17/2022

    ResMed (RMD) today announced Mick Farrell, chief executive officer, will participate in a virtual fireside chat at the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum on Tuesday, March 22, 2022, beginning at approximately 1:30 p.m. via webcast.
  12. Show article details.

    ResMed’s Global Sleep Surveys Reveal What’s Keeping Us Up at Night; Aim to Bring Awareness to the State of Sleep Health for World Sleep Day

    GlobeNewswire – 9:00 AM ET 03/14/2022

    SAN DIEGO, March 14, 2022 -- ResMed (RMD) announced today the results of its 2022 Global Sleep Surveys, in conjunction with National Sleep Awareness Week and World Sleep Day. Across most countries, a majority of respondents reported stress has had an impact on their sleep since the start of the pandemic, with a high of 64% in Brazil and a low of 35% in Germany and Japan.
  13. Show article details.

    ResMed Announces Participation in the Oppenheimer 32nd Annual Healthcare Conference

    GlobeNewswire – 9:00 AM ET 03/10/2022

    ResMed (RMD) today announced Rob Douglas, president and chief operating officer, will present at the Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15, 2022, beginning at approximately 1:20 p.m. via webcast.
  14. Show article details.

    ResMed Announces Participation in the Citi Healthcare Conference

    GlobeNewswire – 9:00 AM ET 02/16/2022

    ResMed (RMD) today announced Mick Farrell, chief executive officer, will participate in a virtual fireside chat at the Citi Healthcare Conference on Wednesday, February 23, 2022, beginning at approximately 12:30 p.m. via webcast.
Page:

Today's and Upcoming Events

  • Oct
    26

    RMD to announce Q1 earnings (Unconfirmed)

  • Aug
    17

    RMD ex-Dividend for $0.44 on 08/17/2022

    • Announce Date: 08/11/2022
    • Record Date: 08/18/2022
    • Pay Date: 09/22/2022

Past Events (last 90 days)

  • Aug
    11

    RMD announced Q4 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Classic Patterns (past 90 days)

PROVIDED BY RECOGNIA, INC.

View All Technical Analysis in Advanced Chart Opens in New Window

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.

Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
Copyright 1998–2022 FMR LLC. 
All rights reserved. 
Close
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.